Updated Jul 16, 2026
Jorgensen Nathan D. is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $54K.
Nathan D. Jorgensen is the Chief Financial Officer at Voyager Therapeutics, Inc., a biotechnology company focused on gene therapy for neurological diseases. He has a background in finance and management within the biotech sector, contributing to the company's financial strategy and operations.
| Role | Chief Financial Officer |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-26 | VYGR | Voyager Therapeutics, Inc. | S — Open-market sale | 4.7K | $3.77 | $18K |
| 2026-02-10 | VYGR | Voyager Therapeutics, Inc. | A — Grant or award | 32.2K | $0.00 | |
| 2025-10-03 | VYGR | Voyager Therapeutics, Inc. | S — Open-market sale | 7.7K | $4.78 | $37K |
| 2024-10-02 | VYGR | Voyager Therapeutics, Inc. | A — Grant or award | 80.0K | $0.00 |
Nathan D. Jorgensen is the Chief Financial Officer at Voyager Therapeutics, Inc., a biotechnology company focused on gene therapy for neurological diseases. He has a background in finance and management within the biotech sector, contributing to the company's financial strategy and operations.…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($54K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Jorgensen Nathan D. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.